Q-omics provides the consensus-scored SEMA3C profile across patient tissues and cancer cell-line models. SEMA3C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SEMA3C is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SEMA3C RNA expression shows 20,527 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight CESC, HNSC, and BRCA as cancer lineages where SEMA3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA3C survival associations across molecular data types. SEMA3C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA3C RNA expression–survival associations across cancer types. High SEMA3C expression shows unfavorable associations in CESC, HNSC, KIRP, PAAD and KIRC, but favorable associations in BRCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SEMA3C RNA expression.
This table summarizes SEMA3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SEMA3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA3C shows lower tumor expression in KIRC, BRCA and COAD and higher tumor expression in HNSC, KICH and LUAD. The HNSC box plot shows higher SEMA3C RNA expression in tumor versus normal tissue (log2 FC = +2.704, t-test p < 0.001).
This table shows molecular features associated with SEMA3C in patient tissues and cancer cell lines. In patient samples, SEMA3C shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
